Cross-source evidence timeline

Orforglipron research timeline

Follow 33 selected, directly cited source records from July 1, 2025 through November 9, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

33Selected records
2Source years
3Evidence lanes
November 9, 2026Latest source date

Source year

2026

30 records
  1. Literature metadata

    Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.↗

    PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Orforglipron for Obstructive Sleep Apnea: Research Summary.↗

    PubMed lists PMID 43002163 in JAMA as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT07794579↗

    PeptideScanner retained ClinicalTrials.gov record NCT07794579 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT06672549↗

    PeptideScanner retained ClinicalTrials.gov record NCT06672549 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT06672939↗

    PeptideScanner retained ClinicalTrials.gov record NCT06672939 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT07202884↗

    PeptideScanner retained ClinicalTrials.gov record NCT07202884 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT07223593↗

    PeptideScanner retained ClinicalTrials.gov record NCT07223593 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT07241390↗

    PeptideScanner retained ClinicalTrials.gov record NCT07241390 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT06192108↗

    PeptideScanner retained ClinicalTrials.gov record NCT06192108 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT07790861↗

    PeptideScanner retained ClinicalTrials.gov record NCT07790861 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT07153471↗

    PeptideScanner retained ClinicalTrials.gov record NCT07153471 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT07613307↗

    PeptideScanner retained ClinicalTrials.gov record NCT07613307 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  13. Clinical trials

    ClinicalTrials.gov record NCT06109311↗

    PeptideScanner retained ClinicalTrials.gov record NCT06109311 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  14. Clinical trials

    ClinicalTrials.gov record NCT06649045↗

    PeptideScanner retained ClinicalTrials.gov record NCT06649045 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  15. Clinical trials

    ClinicalTrials.gov record NCT05872620↗

    PeptideScanner retained ClinicalTrials.gov record NCT05872620 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  16. Clinical trials

    ClinicalTrials.gov record NCT05971940↗

    PeptideScanner retained ClinicalTrials.gov record NCT05971940 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  17. Clinical trials

    ClinicalTrials.gov record NCT07739537↗

    PeptideScanner retained ClinicalTrials.gov record NCT07739537 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  18. Clinical trials

    ClinicalTrials.gov record NCT05869903↗

    PeptideScanner retained ClinicalTrials.gov record NCT05869903 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  19. Literature metadata

    Orforglipron (Foundayo) for adults with obesity.↗

    PubMed lists PMID 42420063 in Trends in pharmacological sciences as Journal Article, with publication-date metadata of 2026-07-08 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  20. Clinical trials

    ClinicalTrials.gov record NCT06993792↗

    PeptideScanner retained ClinicalTrials.gov record NCT06993792 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  21. Clinical trials

    ClinicalTrials.gov record NCT06972459↗

    PeptideScanner retained ClinicalTrials.gov record NCT06972459 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  22. Clinical trials

    ClinicalTrials.gov record NCT07729332↗

    PeptideScanner retained ClinicalTrials.gov record NCT07729332 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  23. Literature metadata

    Orforglipron Calcium.↗

    PubMed lists PMID 42138709 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2026-07-22 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  24. Clinical trials

    ClinicalTrials.gov record NCT05931380↗

    PeptideScanner retained ClinicalTrials.gov record NCT05931380 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  25. Clinical trials

    ClinicalTrials.gov record NCT06370728↗

    PeptideScanner retained ClinicalTrials.gov record NCT06370728 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  26. Clinical trials

    ClinicalTrials.gov record NCT06440980↗

    PeptideScanner retained ClinicalTrials.gov record NCT06440980 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  27. Clinical trials

    ClinicalTrials.gov record NCT06010004↗

    PeptideScanner retained ClinicalTrials.gov record NCT06010004 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  28. Clinical trials

    ClinicalTrials.gov record NCT06704763↗

    PeptideScanner retained ClinicalTrials.gov record NCT06704763 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-26, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  29. Clinical trials

    ClinicalTrials.gov record NCT06186622↗

    PeptideScanner retained ClinicalTrials.gov record NCT06186622 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was orforglipron.↗

  30. Regulatory

    Drugs@FDA application NDA220934↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.↗

Source year

2025

3 records
  1. Literature metadata

    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.↗

    PubMed lists PMID 38091541 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.↗

    PubMed lists PMID 38091542 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.↗

    PubMed lists PMID 38091543 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗